Sage Therapeutics Inc (SAGE)
11.70
-0.31
(-2.58%)
USD |
NASDAQ |
May 17, 16:00
11.70
0.00 (0.00%)
After-Hours: 20:00
Sage Therapeutics Cash from Operations (Quarterly): -37.83M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -37.83M |
| December 31, 2023 | -119.52M |
| September 30, 2023 | -135.87M |
| June 30, 2023 | -131.52M |
| March 31, 2023 | -153.68M |
| December 31, 2022 | -126.93M |
| September 30, 2022 | -118.86M |
| June 30, 2022 | -106.44M |
| March 31, 2022 | -107.80M |
| December 31, 2021 | -97.50M |
| September 30, 2021 | -68.83M |
| June 30, 2021 | -102.77M |
| March 31, 2021 | -109.09M |
| December 31, 2020 | 1.011B |
| September 30, 2020 | -91.02M |
| June 30, 2020 | -118.98M |
| March 31, 2020 | -136.69M |
| December 31, 2019 | -116.73M |
| September 30, 2019 | -128.70M |
| June 30, 2019 | -133.34M |
| March 31, 2019 | -149.93M |
| December 31, 2018 | -101.78M |
| September 30, 2018 | -80.19M |
| Date | Value |
|---|---|
| June 30, 2018 | -0.135M |
| March 31, 2018 | -78.57M |
| December 31, 2017 | -58.90M |
| September 30, 2017 | -46.09M |
| June 30, 2017 | -59.08M |
| March 31, 2017 | -55.21M |
| December 31, 2016 | -33.78M |
| September 30, 2016 | -30.80M |
| June 30, 2016 | -26.67M |
| March 31, 2016 | -27.44M |
| December 31, 2015 | -18.12M |
| September 30, 2015 | -19.52M |
| June 30, 2015 | -18.44M |
| March 31, 2015 | -14.61M |
| December 31, 2014 | -8.667M |
| September 30, 2014 | -7.486M |
| June 30, 2014 | -5.273M |
| March 31, 2014 | -5.616M |
| December 31, 2013 | -5.039M |
| September 30, 2013 | -5.171M |
| June 30, 2013 | -4.266M |
| March 31, 2013 | -3.04M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-153.68M
Minimum
Mar 2023
1.011B
Maximum
Dec 2020
-56.56M
Average
-117.80M
Median
Cash from Operations (Quarterly) Benchmarks
| Biogen Inc | 553.20M |
| Vanda Pharmaceuticals Inc | 7.569M |
| Ligand Pharmaceuticals Inc | 18.73M |
| ADMA Biologics Inc | -2.218M |
| Axsome Therapeutics Inc | -53.47M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 139.44M |
| Cash from Financing (Quarterly) | 1.557M |
| Free Cash Flow | -424.74M |
| Free Cash Flow Per Share (Quarterly) | -0.6291 |
| Free Cash Flow to Equity (Quarterly) | -37.83M |
| Free Cash Flow Yield | -60.55% |